Showing posts with label plasma lipids and lipoproteins. Show all posts
Showing posts with label plasma lipids and lipoproteins. Show all posts

Saturday, 26 February 2011

Plasma lipids and lipoproteins

Taken from: http://ethesis.helsinki.fi/

2.1. Plasma lipids and lipoproteins


Lipids play very important roles in maintaining the structure of cell membrane (cholesterol, phospholipids), cell growth (cholesterol), steroid hormone synthesis (cholesterol), and energy metabolism (triglycerides). Since lipids are highly hydrophobic, they have to be packed into lipoproteins as water-soluble particles in blood circulation (Gotto et al. 1986). A lipoprotein is a particle consisting of a core of hydrophobic lipids, i.e., triglycerides (TG), cholesteryl esters (CE), surrounded by a polar layer of phospholipids (PL), unesterified cholesterol (FC), and apolipoprotein(s) (Ginsberg 1990). Plasma lipoproteins are usually classified into five major subfractions based on their density (d), particle size, flotation rate (Sf), and electrophoretic mobility in agarose gel. Routinely, the lipoproteins are separated by sequential ultracentrifugation (Havel et al. 1955).

Table 1. Properties and apolipoprotein composition of the major human plasma lipoproteins


CMs are derived from dietary lipids (exogenous pathway) and assembled in the intestinal epithelial cells. TGs are the major constituents of the CM particles. The TGs in CM are hydrolyzed in the peripheral tissues by lipoprotein lipase (LPL) to form the CM remnants which are taken up by the liver in a process that probably involves apolipoprotein E (apoE) on the surface of the remnants and a hepatic receptor called LDL receptor-related protein (LRP) (Beisiegel 1995). VLDL particles are synthesized in the liver (endogenous pathway). They are the main liver-derived TG-rich lipoproteins and in circulation, their TGs are hydrolyzed by LPL and the VLDLs are then degraded into CE-enriched particles called IDL (Gotto et al. 1986). About half of the IDL particles are taken up by the liver via LDL receptor and remnant receptor (van Berkel et al. 1995), whereas the other half are converted into LDL by hepatic lipase (HL) (Taskinen and Kuusi 1987). LDLs are the major carriers of cholesterol in plasma. LDL metabolism is discussed in more detail in Section 2.2.2. Lipoprotein (a) [Lp(a)], which consists of an LDL particle covalently attached to apolipoprotein (a) [apo(a)], is a distinct class of CE-rich plasma lipoprotein. It can bind weakly to LDL receptors and play a role in the genesis of atherosclerosis (Jauhiainen et al. 1991).

HDLs consist of apoAI and apoAII as the main apolipoprotein constituents and carry about 20% cholesterol, most of which are CE (Ginsberg 1990). HDLs are synthesized in the liver and intestine (Franceschini et al. 1991). Also HDLs can be generated following the lipolysis of TG-rich lipoproteins whereafter plasma phospholipid transfer protein (PLTP) facilitates the transfer of phospholipids and some cholesterol into HDL pool (Eisenberg 1984, Jiang et al. 1999). In addition, the lecithin-cholesterol acyltransferase (LCAT) has a crucial role in the maturation of HDL particles. LCAT can catalyze the formation of CE which are then incorporated into the core of discoidal nascent HDL (Franceschini et al. 1991). HDLs (especially preß-mobile HDL) play a major role in the transport of cholesterol from peripheral tissues to the liver, a process known as reverse cholesterol transport (Tall 1990). HDL CE are transfered by cholesteryl ester transfer protein (CETP) to apoB-containing particles which are finally removed from the circulation by the liver (Tall 1993). In addition, HDLs can be taken up by class B scavenger receptor (SR-BI)-mediated process in certain cells where this receptor mediates selective CE uptake leaving the HDL particles largely intact (Acton et al. 1996, Krieger 1998), or directly removed by the liver (Tall 1992).

Clinical Chemistry in Diagnosis and Treatment (1994) Philip D Mayne

Call No: QY90 Z69 1994 

Author: Philip D. Mayne
Publisher: Oxford Univ Pr
Publication Date: 1994-01-01
Language: English
Format: Paperback
ISBN-10: 0340576472
ISBN-13: 9780340576472
Product ID: EPID48049310


Topics of interest

Chapter 11: Plasma Lipids and Lipoproteins
(pages 223-241)
Terminology (page 224)
Plasma Lipids (pages 224-5)
- Fatty acids
- Triglycerides
- Phospholipids
- Cholesterol
- Fig 11.1: Chemical structure of lipids present in plasma
- Table 11.1: Fatty acids present in plasma


Lipoproteins (pages 225-6; 227)
- Chylomicrons
- VLDL
- IDL
- LDL
- HDL
- Table 11.2: The composition and electrophoretic mobility of the main lipoprotein particles
- Table 11.3: WHO (Fredrickson) classification of hyperlipidaemia, based on the electrophoretic pattern of the lipoproteins 
- Table 11.4: The main apolipoproteins and their known functions (page 227)
- Fig 11.2: Exogenous pathway of lipid metabolism (page 228)
- Fig 11.3: Endogenous pathway of lipid metabolism (page 229)
- Fig 11.4: The relation between the cellular uptake of LDL and the endogenous synthesis of cholesterol (page 230)


Metabolism of Lipoproteins (pages 227-231)
- Exogenous Lipid Pathways
- - Chylomicron Metabolism
- Endogenous Lipid Pathways
- - VLDL Metabolism
- - LDL Metabolism
- - Factors Influencing Plasma LDL Concentrations
- Role of HDL


Disorders of Lipid Metabolism (pages 232-236)
- Clinical Manifestation of Hyperlipidaemia
- - arterial walls, subcutaneous tissue, tendons, cornea
- Lipid and Cardiovascular Disease
- Predominant Hypercholesterolaemia
- - What is hypercholesterolaemia?
- - Causes of hypercholesterolaemia
- - - Secondary hypercholesterolaemia
- - - - Table 11.5: The effect of some drugs on plasma lipid concentrations
- - - Primary hypercholesterolaemia
- - - - Familial combined hyperlipidaemia
- - - - Familial (monogenic) hypercholesterolaemia
- Predominant Hypertriglyceridaemia
- - Table 11.6: Some important causes of secondary hypertriglyceridaemia
- - Familial combined hyperlipidaemia
- - Familial endogenous hypertriglyceridaemia
- Mixed Hyperlipidaemia
- Rare Disorders Associated With Lipid Metabolism


Principles of Treatment of Hyperlipidaemia (pages 236-7)
- General Measures
- - Hypercholesterolaemia
- - - Restriction of dietary animal fats, eggs and dairy products
- - - Drug treatment
- - Hypertriglyceridaemia
- - - Dietary restriction
- - - Fibric acid derivatives 


Summary (page 238)


Investigation of Lipid Disorders (pages 239-241)
- Plasma Sampling
- Investigation of Suspected Hyperlipidaemia
- Is The Cause Primary Or Secondary?
- What Is The Nature Of The Abnormality?
- Family Studies
- Treatment